PKN Stock Overview
Provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Revvity, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$107.85 |
| 52 Week High | US$117.55 |
| 52 Week Low | US$78.72 |
| Beta | 1.06 |
| 11 Month Change | 0.79% |
| 3 Month Change | 0.70% |
| 1 Year Change | 32.82% |
| 33 Year Change | -33.45% |
| 5 Year Change | 29.94% |
| Change since IPO | 681.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| PKN | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 4.5% | 3.9% | 0.8% |
| 1Y | 32.8% | 5.4% | 9.1% |
Return vs Industry: PKN exceeded the German Life Sciences industry which returned 3.6% over the past year.
Return vs Market: PKN exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| PKN volatility | |
|---|---|
| PKN Average Weekly Movement | 4.2% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PKN has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: PKN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1937 | 11,500 | Prahlad Singh | www.revvity.com |
Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Revvity, Inc. Fundamentals Summary
| PKN fundamental statistics | |
|---|---|
| Market cap | €12.99b |
| Earnings (TTM) | €246.07m |
| Revenue (TTM) | €2.59b |
54.0x
P/E Ratio5.1x
P/S RatioIs PKN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PKN income statement (TTM) | |
|---|---|
| Revenue | US$2.72b |
| Cost of Revenue | US$1.21b |
| Gross Profit | US$1.51b |
| Other Expenses | US$1.25b |
| Earnings | US$258.26m |
Last Reported Earnings
Sep 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.12 |
| Gross Margin | 55.37% |
| Net Profit Margin | 9.49% |
| Debt/Equity Ratio | 40.2% |
How did PKN perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield13%
Payout RatioDoes PKN pay a reliable dividends?
See PKN dividend history and benchmarks| Revvity dividend dates | |
|---|---|
| Ex Dividend Date | Jan 17 2025 |
| Dividend Pay Date | Feb 07 2025 |
| Days until Ex dividend | 51 days |
| Days until Dividend pay date | 72 days |
Does PKN pay a reliable dividends?
See PKN dividend history and benchmarks